The Levitronix CentriMag ventricular assist device as a bridge to decision in patients with end-stage heart failure: Our single-center experience

Abstract

Background: In this study, we report early outcomes of Levitronix CentriMag device implantation for bridge to decision for patients with end-stage heart failure in a single center. Methods: We retrospectively analyzed data of a total of 41 patients (30 males, 11 females: mean age 30.2 +/- 15 years; range 7 to 59 years) with end-stage heart failure who received a Levitronix CentriMag support for bridge to decision between December 2010 and September 2014. Devices were implanted in the left (n=38), right (n=1), or biventricular (n=2) configuration. Support was continued until recovery, transplantation or implantation of a long-term ventricular assist device. Results: The mean preoperative left ventricular ejection fraction was 17 +/- 2.3%. The mean support time was 38 (range 1 to 192) days. Sixteen patients (39%) survived and moved on to the next phase of the treatment. Of these patients, 11 (27%) underwent cardiac transplantation operations and five (12%) received long-term ventricular assist devices. After the CentriMag implantation, 30-day survival rate was 49% in 20 patients. Bleeding requiring re-operation was observed in 13 patients (32%). Two patients (4.8%) had sternal wound infections. Device dysfunction was observed in one patient (2.4%). Non-survivors had a higher rate of sepsis and renal failure, compared to the survivors (p<0.05). Conclusion: The CentriMag system provides an effective temporary mechanical circulatory support for cardiac failure. The ease of implantation and high rate of successful device weaning encourage the use of CentriMag system as a temporary ventricle support.